This was posted by Spencer on YMB about 1 hour ago
Post# of 154116
(Total Views: 1170)
Posted On: 11/17/2021 11:15:30 AM
This was posted by Spencer on YMB about 1 hour ago.
Soooo. For all you speculators, thoughtless people and outright liars that are on this board here is the real story of the Canadian Cancer Patient. She has been taking Leronlimab since September 2020. She started on Leronlimab as part of a trial and when the trial ended she and her oncologist had to apply for the Canadian Special Access Program to stay on Leronlimab. If she was in the US the application would have been under Right to Try. The approval for the SAP was granted one month ago. She has been on Leronlimab for 14 months and she has been No Evidence of Disease - NED for exactly one year now. This is the first time Leronlimab has received this type of approval in Canada. This does potentially open the door for other cancer patients to apply under the same legislation as the first approval is definitely the hardest. It took Health Canada 6 weeks to make the decision. I know these are the facts because I know her personally.
Soooo. For all you speculators, thoughtless people and outright liars that are on this board here is the real story of the Canadian Cancer Patient. She has been taking Leronlimab since September 2020. She started on Leronlimab as part of a trial and when the trial ended she and her oncologist had to apply for the Canadian Special Access Program to stay on Leronlimab. If she was in the US the application would have been under Right to Try. The approval for the SAP was granted one month ago. She has been on Leronlimab for 14 months and she has been No Evidence of Disease - NED for exactly one year now. This is the first time Leronlimab has received this type of approval in Canada. This does potentially open the door for other cancer patients to apply under the same legislation as the first approval is definitely the hardest. It took Health Canada 6 weeks to make the decision. I know these are the facts because I know her personally.
(31)
(0)